Thymus Carcinoma

Heavily pretreated patient with advanced thymic carcinoma was responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). and carried a c-kit missense mutation on exon 17 (D820E).

PMID 19461405 · Bisagni et al., 2009 · Open in CIViC

Efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion (P577-D579DEL) mutation.

PMID 20970876 · Dişel et al., 2011 · Open in CIViC

A patient with a c-kit mutation-positive (V559G) thymic carcinoma received imatinib followed by sunitinib consecutively, and achieved long-term disease control for 27 months.

PMID 27073655 · Hirai et al., 2016 · Open in CIViC

An advanced thymic squamous cell carcinoma patient harboring a KIT V559G mutation was associated with partial response to sunitinib monotherapy. Upon identification of the KIT V559G mutation, the pat… (full text at CIViC)

PMID 27073655 · Hirai et al., 2016 · Open in CIViC

In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib.

PMID 15201427 · Ströbel et al., 2004 · Open in CIViC

Thymic Carcinoma with Overexpression of Mutated KIT (V560DEL) and the Response to Imatinib

PMID 15201427 · Ströbel et al., 2004 · Open in CIViC

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated (Y553N) thymic carcinoma.

PMID 21969494 · Buti et al., 2011 · Open in CIViC